CAMBRIDGE, Mass.--(BUSINESS WIRE)--ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem.

马萨诸塞州剑桥市。-（商业新闻短讯）--ReNAgade Therapeutics是一家挖掘RNA药物无限潜力的公司，今天宣布，它正在致力于通过支持GanNA Bio正在进行的研究以及将GanNA Bio的关键个体整合到ReNAgade生态系统中来探索糖生物学的治疗机会。

GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade..

甘纳州创始人卡罗琳·贝托齐（CarolynBertozzi）博士和理查德·卡明斯（RichardD.Cummings）博士现在将担任ReNAgade的顾问。。

“ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines.

ReNAgade联合创始人布赖恩·古德曼（BrianGoodman）表示：“ReNAgade将继续从GanNA在开发肝外递送技术方面的有前途的工作中受益匪浅，该技术有助于扩大我们自己的RNA药物的广度和潜力。”。“交付是ReNAgade克服RNA药物当前局限性的使命的基础。

We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.”.

我们相信，随着我们继续推进我们独特的综合治疗平台，GanNA内部开发的技术将有助于进一步巩固ReNAgade的领导地位。”。

Formed in 2021 and invested in by ReNAgade, GanNA Bio harnesses novel glycobiology to enable extra-hepatic RNA delivery based on pioneering research licensed from Stanford University, Boston Children’s Hospital, and Beth Israel Deaconess Medical Center. This research was developed in the labs of Carolyn Bertozzi, Ph.D., winner of the 2022 Nobel Prize in Chemistry and Professor of Chemistry in the Stanford School of Humanities and Sciences; Ryan A.

GanNA Bio成立于2021年，由ReNAgade投资，基于斯坦福大学，波士顿儿童医院和贝斯以色列女执事医疗中心许可的开创性研究，利用新型糖生物学实现肝外RNA递送。这项研究是在CarolynBertozzi博士的实验室中开发的，CarolynBertozzi博士是2022年诺贝尔化学奖获得者，斯坦福大学人文科学学院化学教授；瑞安A。

Flynn, M.D., Ph.D., Assistant Professor at Boston Children’s Hospital; and Richard D. Cummings, Ph.D., S. Daniel Abraham Professor of Surgery at Beth Israel Deaconess Medical Center, and led by Namita Bisaria, Ph.D, M.B.A., a serial entrepreneur in the RNA therapeutics field. Its platform, based on new advances in glycobiology and synthesis, uses cell-specific glycans to develop next-generation conjugates and unlock the delivery of short and long stranded RNA medicines..

弗林，医学博士，博士，波士顿儿童医院助理教授；和Richard D.Cummings博士、S.Daniel Abraham Beth Israel Deaconess Medical Center外科教授，由RNA治疗领域的连续企业家Namita Bisaria博士领导。其平台基于糖生物学和合成的新进展，使用细胞特异性聚糖开发下一代结合物，并解锁短链和长链RNA药物的递送。。

“The combination of GanNA’s innovative glycobiology-based targeting strategy with ReNAgade’s experience in the development of RNA medicines will be a powerful combination for the benefit of patients,” said Dr. Bertozzi. 'The progress in glycoRNA science from our seminal publication in the journal Cell is moving fast, and integration with ReNAgade’s pipeline will strengthen our position to develop a broad portfolio of cell-specific delivery systems, leveraging the latest developments in glycobiology in order to expand the array of addressable diseases for RNA medicines.

贝托齐博士说：“甘纳创新的基于糖生物学的靶向策略与雷纳德在RNA药物开发方面的经验相结合，将是对患者有益的有力结合。”我们在Cell杂志上发表的开创性出版物在glycoRNA科学方面取得的进展正在迅速取得进展，与ReNAgade的管道整合将加强我们开发广泛的细胞特异性递送系统组合的地位，利用糖生物学的最新发展，以扩大RNA药物的可寻址疾病阵列。

Glycobiology-based RNA medicines represent a new frontier, and it is rewarding to see the possibilities of ReNAgade developing these for clinical use.”.

基于糖生物学的RNA药物代表了一个新的前沿，看到ReNAgade开发这些药物用于临床的可能性是值得的。”。

About ReNAgade Therapeutics

关于ReNAgade Therapeutics

ReNAgade exists to unlock the potential for RNA medicines to treat disease anywhere in the body. We combine our novel RNA delivery platforms with a comprehensive RNA platform allowing for an all-RNA system for coding, editing, and gene insertion to develop new medicines.

ReNAgade的存在是为了释放RNA药物治疗身体任何部位疾病的潜力。我们将我们新颖的RNA传递平台与全面的RNA平台相结合，从而实现了用于编码，编辑和基因插入的全RNA系统，以开发新药。

To accelerate the future of medicine, we bring together a team with deep RNA and delivery expertise to develop paradigm-shifting RNA medicines.

为了加速医学的未来，我们召集了一个具有深度RNA和递送专业知识的团队，开发范式转变的RNA药物。

ReNAgade Therapeutics—RNA Without Limits

ReNAgade Therapeutics RNA无限制

For more information about the company, its technologies, and its leadership, visit www.renagadetx.com

有关该公司、其技术和领导力的更多信息，请访问www.renagadetx.com

About GanNA Bio

关于甘纳生物

GanNA was created by Drs. Flynn and Bisaria, and invested by ReNAgade in 2021 following a sponsored research agreement in the lab of Dr. Flynn. The mission is to explore the potential of novel glycobiology therapies following the pioneering work at Stanford University by Drs. Flynn and Bertozzi on glycoRNA.

GanNA由Flynn博士和Bisaria博士创建，ReNAgade于2021年根据Flynn博士实验室的赞助研究协议进行投资。该任务是在斯坦福大学弗林博士和贝尔托齐博士在glycoRNA方面的开创性工作之后，探索新型糖生物学疗法的潜力。

The GanNA Bio Scientific Advisory Board included Drs. Bertozzi, Cummings, Flynn, and ReNAgade CSO, Pete Smith..

甘纳州生物科学咨询委员会包括Bertozzi博士、Cummings博士、Flynn博士和ReNAgade CSO、Pete Smith博士。。

University Conflict of Interest Disclosure

大学利益冲突披露

Drs. Bertozzi, Cummings and Flynn consult for ReNAgade Therapeutics.

Bertozzi博士，Cummings博士和Flynn博士咨询ReNAgade Therapeutics。